IFNA1 and melanoma: In both these two studies in patients with advanced melanoma, IFN-α 2b (3–6 million units) was administered s.c. at the time of repeated i.d. injections of the melanoma peptides, with the main rationale of inducing DC activation, thus promoting an antitumor immune response.